

1 **MS #27051** (accepted author manuscript of the article published in J Gen Intern Med 2019.
2 doi: 10.1007/s11606-019-05096-2)

3
4 **Screening refusal associated with choice of colorectal cancer screening**
5 **methods. A cross-sectional study among Swiss primary care physicians.**

6
7 Yonas Martin, MMed^{1,2}, Alexander Leonhard Braun, MMed¹, Nikola Biller-Andorno, MD, PhD³, Jean-
8 Luc Bulliard, PhD⁴, Jacques Cornuz, MD, MPH⁵, Kevin Selby, MD⁵, Reto Auer, MD, MAS^{1,5}

9 ¹Institute of primary health care (BIHAM), University of Bern, Bern, Switzerland, ²Department of
10 General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland,

11 ³Institute for Biomedical Ethics and History of Medicine (IBME), UZH, Zürich, Switzerland, ⁴Institute of
12 Social and Preventive Medicine (IUMSP), University of Lausanne, Lausanne, Switzerland,

13 ⁵Department of Ambulatory Care and Community Medicine, University of Lausanne, Lausanne,
14 Switzerland

15
16 Corresponding Author:

17 Yonas Martin, MMed

18 Institute of primary health care (BIHAM), University of Bern

19 Mittelstrasse 43

20 CH - 3012 Bern

21 yonas.martin@biham.unibe.ch

22 +41 31 631 58 79

23
24 Figures: 2 (Max 2 tables or figures)

25 Text word length: 698 (Max 700)

26 References: 6 (Max. 6)

27
28
29 Key words: primary care, colorectal cancer, screening, practice variation, patient preferences

30
31 Running title: Colorectal cancer screening in primary care

37 **Introduction**

38 Guidelines recommend primary care physicians (PCPs) offer patients a choice of colorectal
39 cancer (CRC) screening methods, including colonoscopy and fecal occult blood tests (FOBT).(1)
40 However, in countries like the US and Switzerland, patients are screened almost exclusively
41 with colonoscopy.(2, 3) When offered both tests, patients appear as likely to choose one as
42 the other; the predominance of colonoscopy may largely be explained by physician preference
43 and local medical culture.(4) Offering only colonoscopy might explain why screening rates are
44 low.

45 We sought to determine the proportions of patients who opted for screening with
46 colonoscopy or FOBT and who refused testing among 50-75-year-olds eligible for screening at
47 a PCP visit. We described variation in care between PCPs and tried to identify PCP-level factors
48 associated with testing method and refusal.

49 **Methods**

50 We conducted a cross-sectional data collection on CRC screening practices at PCP-level. We
51 invited 129 PCPs from the Swiss Sentinel Surveillance Network (Sentinella) to fill a structured
52 data collection form for 40 consecutive non-emergent consultations with 50-75-year-old
53 patients. The federal office of public health (FOPH) provided demographic data at PCP level.
54 PCPs reported demographic data at patient-level, data on previous CRC tests, contra-
55 indications for screening, risk factors for CRC, if CRC screening was discussed, choice of test
56 (colonoscopy, FOBT, other), and refusal for testing. We calculated overall proportions and
57 reported variation between PCPs in the proportion of FOBT vs. colonoscopy they prescribed
58 to patients who chose to be tested. We calculated overall prescription rates of FOBT vs.
59 colonoscopy for each PCP, including both patients who had already undergone screening and
60 patients prescribed screening after the consultation. We dichotomized this covariate by
61 never-prescription of FOBT (no patients previously tested with FOBT or prescribed FOBT after
62 discussion) vs. any FOBT.

63 We used mixed-effects logistic regression models that allowed us to cluster the data by PCP
64 (with PCPs modeled as a random effect) to explore the association between PCP
65 characteristics and the proportion of patients who refused screening after discussion. We
66 adjusted the models for PCPs' demographics (age, sex) and language region, for patients'
67 demographics (age, sex), and PCPs' prescription patterns.

68

69 **Results**

70 91 PCPs (71% of invited, mean age:54, 24% women) collected data on 3,637 patients. 186
71 patients were excluded because they were not aged 50-75 y.o. or had already been seen
72 during data collection. 3,453 patients were included in the analysis (mean age:63, 50%
73 women). PCPs discussed screening with 51% (874/1727) of eligible patients (not up-to-date
74 and no contra-indications for testing) (Figure 1). After excluding patients with risk factors or
75 symptoms suggestive of CRC (n=104), 61% (473/770) opted for screening (FOBT/colonoscopy
76 ratio:0.5), 29% refused, 6% were undecided and 3% were unspecified or missing. Most
77 patients who refused screening said they did so because they didn't feel concerned.

78 33 PCPs (36%) had none of their patients previously tested with FOBT or who planned to be
79 tested with FOBT. Patients of PCPs who only offered colonoscopy were more likely to refuse
80 screening than patients of PCPs who offered both colonoscopy and FOBT (44%vs.20%,
81 respectively, Figure 2). These results were confirmed in our mixed-effects multivariate model
82 (OR:3.90,95%CI:1.90 to 8.00,p<0.001). No other PCPs characteristics were associated with
83 chosen testing methods or refusal rates.

84 **Discussion**

85 When PCPs discussed CRC screening with their 50-75-year-old patients who were not up-to-
86 date with screening, had no contraindication and no risk factors for CRC, a third of their
87 patients declined to be screened. PCPs who only offered colonoscopy had lower screening
88 rates (47% vs. 71%) and higher refusal rates (44% vs. 20%) than PCPs who offered both
89 colonoscopy and FOBT. These results are in line with a randomized controlled trial showing
90 lower uptake rates of CRC screening tests among patients who are offered only colonoscopy
91 vs. among the ones who are offered both FOBT and colonoscopy (5). We were inherently
92 limited in considering additional patient-level sociodemographic factors by the simplicity and
93 anonymity of our data collection.

94 Encouraging PCPs to offer both methods could reduce the number of physicians who only
95 prescribe one screening modality, reduce variation between practices, and allow more
96 patients to choose the test that matches their preferences and values.(4, 6) This could reduce
97 the number of refusals, raise CRC screening rates, and ultimately lower the burden of CRC.

98

99 Acknowledgements

100 *Contributors:* We thank the primary care physicians from the Sentinella network and the
101 Sentinella administration as well as the Section Notification Systems at the Federal Office of
102 Public Health for their help collecting this data. We thank Kali Tal for the thorough editing of
103 this work. We thank Emanuele Prati for his help in the data collection. We thank Charles
104 Dvořák for the great help in the conduction of the study among Sentinella PCPs. We thank
105 Cyril Ducros for his comments to this work.

106

107 *Funders:* This work was supported by the funds from the Swiss National Scientific Foundations
108 National Research Plan 74 NFP74. 407440_167519. The funders had no role in the design or
109 conduct of the study, in the collection, management, analysis, or interpretation of data, nor
110 in the preparation, review or approval of the manuscript.

111

112 *Prior presentations:* An earlier version of the abstract was presented at the Wennberg
113 International Conference (WIC) in Zürich, Switzerland in April 2018 and at the Swiss Society of
114 General Internal Medicine (SSGIM) meeting in Basel, Switzerland in May 2018. The abstract
115 was presented at the European Society of Medical Decision Making (SMDM) conference in
116 Leiden, Netherlands, in June 2018. This work was presented as oral presentation at the
117 American Society of Medical Decision Making (SMDM) Conference in Montreal in October
118 2018.

119

120 Conflict of interest

121 None of the authors has a conflict of interest related to this manuscript.

122 **References:**

123

124 1. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, Jr., Garcia FAR, et al.
125 Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.
126 JAMA. 2016;315(23):2564-75. doi:10.1001/jama.2016.5989

127 2. Fedewa SA, Cullati S, Bouchardy C, Welle I, Burton-Jeangros C, Manor O, et al. Colorectal
128 Cancer Screening in Switzerland: Cross-Sectional Trends (2007-2012) in Socioeconomic Disparities.
129 PLoS ONE. 2015;10(7):e0131205. doi:10.1371/journal.pone.0131205

130 3. McQueen A, Bartholomew LK, Greisinger AJ, Medina GG, Hawley ST, Haidet P, et al. Behind
131 Closed Doors: Physician-Patient Discussions About Colorectal Cancer Screening. Journal of General
132 Internal Medicine. 2009;24(11):1228-35. doi:10.1007/s11606-009-1108-4

133 4. Selby K, Cornuz J, Gachoud D, Bulliard JL, Nichita C, Dorta G, et al. Training primary care
134 physicians to offer their patients faecal occult blood testing and colonoscopy for colorectal cancer
135 screening on an equal basis: a pilot intervention with before-after and parallel group surveys. BMJ
136 Open. 2016;6(5):e011086. doi:10.1136/bmjopen-2016-011086

137 5. Inadomi JM, Vijan S, Janz NK, Fagerlin A, Thomas JP, Lin YV, et al. Adherence to colorectal
138 cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med.
139 2012;172(7):575-82. doi:10.1001/archinternmed.2012.332

140 6. Mulley AG, Trimble C, Elwyn G. Stop the silent misdiagnosis: patients' preferences matter.
141 Bmj. 2012;345:e6572.

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161 **Figure legends**

162 **Figure 1-** Flowchart of 40 consecutive patients aged 50-75 included by PCPs from the
163 Sentinella network from in 2017.*

164 * PCPs collected data on 40 consecutive patients aged 50-75 from on past screening status,
165 contraindications for screening, if a discussion on CRC screening could take place, RF and
166 symptoms for CRC and the decision taken (refusal, FOBT, colonoscopy, other). Data collected
167 between April and December 2017. a RF = Risk factor for CRC

168

169 **Figure 2** – Decision patterns among patients who had a discussion on CRC screening (N
170 patients=770) and included by PCPs who only prescribed colonoscopy (N=33) vs PCPs who
171 prescribed both colonoscopy and FOBT (N=58), in the Sentinella Network in 2017*

172 * Patients with risk factors or symptoms suggestive for CRC (n=104) (see Figure 1) excluded
173 of this analysis

174

175

176

177

178

179

180

181

182

183